Karl Sandström
Consultant at Department of Surgical Sciences; Otorhinolaryngology and Head and Neck Surgery
- E-mail:
- karl.sandstrom@uu.se
- Visiting address:
- Akademiska sjukhuset, ingång 7879
751 85 Uppsala - Postal address:
- Akademiska sjukhuset, ingång 7879
751 85 Uppsala
More information is available to staff who log in.
Keywords
- cancer
- surgery
Publications
Selection of publications
- In vivo characterization of the novel CD44v6-targeting Fab fragment AbD15179 for molecular imaging of squamous cell carcinoma (2014)
- A novel CD44v6 targeting antibody fragment with improved tumor-to-blood ratio (2012)
- Improved Tumor-to-Organ Ratios of a Novel 67Ga-Human Epidermal Growth Factor Radionuclide Conjugate with Preadministered Antiepidermal Growth Factor Receptor Affibody Molecules (2011)
- Blocking EGFR in the liver improves the tumor-to-liver uptake ratio of radiolabeled EGF (2010)
- Targeting CD44v6 expressed in head and neck squamous cell carcinoma (2008)
Recent publications
- Prognostic value of bone marrow and tumor 18F‐FDG uptake on PET/CT in patients with oropharyngeal cancer and the interplay between inflammation and FDG uptake (2024)
- Squamous cell carcinoma of the mobile tongue in young adults (2023)
- Loco-Regional Control and Sustained Difference in Serum Immune Protein Expression in Patients Treated for p16-Positive and p16-Negative Head and Neck Squamous Cell Carcinoma (2023)
- Serum Proteomics in Patients with Head and Neck Cancer (2022)
- Base of tongue squamous cell carcinomas, outcome depending on treatment strategy and p16 status. A population-based study from the Swedish Head and Neck Cancer Register (2022)
All publications
Articles
- Prognostic value of bone marrow and tumor 18F‐FDG uptake on PET/CT in patients with oropharyngeal cancer and the interplay between inflammation and FDG uptake (2024)
- Squamous cell carcinoma of the mobile tongue in young adults (2023)
- Loco-Regional Control and Sustained Difference in Serum Immune Protein Expression in Patients Treated for p16-Positive and p16-Negative Head and Neck Squamous Cell Carcinoma (2023)
- Serum Proteomics in Patients with Head and Neck Cancer (2022)
- Base of tongue squamous cell carcinomas, outcome depending on treatment strategy and p16 status. A population-based study from the Swedish Head and Neck Cancer Register (2022)
- Mandibular resection in patients with head and neck cancer (2022)
- Mapping of human papilloma virus, p16, and epstein-barr virus in non-malignant tonsillar disease (2019)
- Transoral Robotic Surgery in the Nordic Countries (2018)
- Distribution and Molecular Characterization of Human Adenovirus and Epstein-Barr Virus Infections in Tonsillar Lymphocytes Isolated from Patients Diagnosed with Tonsillar Diseases (2016)
- Efficient Isolation Protocol for B and T Lymphocytes from Human Palatine Tonsils (2015)
- In vivo characterization of the novel CD44v6-targeting Fab fragment AbD15179 for molecular imaging of squamous cell carcinoma (2014)
- A novel CD44v6 targeting antibody fragment with improved tumor-to-blood ratio (2012)
- Improved Tumor-to-Organ Ratios of a Novel 67Ga-Human Epidermal Growth Factor Radionuclide Conjugate with Preadministered Antiepidermal Growth Factor Receptor Affibody Molecules (2011)
- Blocking EGFR in the liver improves the tumor-to-liver uptake ratio of radiolabeled EGF (2010)
- Targeting CD44v6 expressed in head and neck squamous cell carcinoma (2008)